Macrolide antibiotics

Reading File

Finding Sources

Searching PubMed

"macrolide" AND "clinical"

Reading File

Finding Sources

Reading File

Loading Image

Reading File

Loading Image

I now have all the information needed for a comprehensive answer. Here is the complete reference on macrolide antibiotics:

Macrolide Antibiotics

Structure

Macrolide antibiotics are defined by a large macrocyclic lactone ring to which one or more deoxy sugars are attached. Ring sizes vary by agent:

14-membered ring: erythromycin, clarithromycin
15-membered ring: azithromycin (technically an "azalide" - the ring contains a methyl-substituted nitrogen atom)

Clarithromycin differs from erythromycin only by methylation of the hydroxyl group at position 6. Azithromycin differs by insertion of a nitrogen atom into the lactone ring. Both structural modifications improve acid stability, tissue penetration, and spectrum of activity compared to erythromycin. - Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 1202

Mechanism of Action

Macrolides are primarily bacteriostatic (bactericidal at high concentrations). They bind reversibly to the 23S rRNA of the 50S ribosomal subunit, blocking bacterial protein synthesis.

The primary effect is inhibition of the translocation step: the newly synthesized peptidyl-tRNA fails to move from the A site to the P (donor) site. Alternatively, macrolides may cause a conformational change that interferes with both transpeptidation and translocation. - Goodman & Gilman's, p. 1202

Their binding site overlaps with that of clindamycin and chloramphenicol, so these agents can competitively displace each other.

Members of the Class

Drug	Ring Size	Key Feature
Erythromycin	14-membered	Original agent (1952); acid labile
Clarithromycin	14-membered	Acid stable; active metabolite (14-OH); twice daily
Azithromycin	15-membered (azalide)	Longest half-life; once daily; least CYP3A4 interaction
Fidaxomicin	Macrocyclic	Non-absorbed; C. difficile only
Telithromycin	Ketolide	Active vs. macrolide-resistant strains; withdrawn in US due to hepatotoxicity

Antimicrobial Spectrum

Typical therapeutic applications of macrolides across gram-positive, gram-negative, atypical, and mycobacterial organisms

Gram-positive organisms:

Streptococcus pneumoniae, S. pyogenes, Corynebacterium diphtheriae, Listeria monocytogenes, Clostridium perfringens

Gram-negative organisms:

Moraxella catarrhalis, Neisseria gonorrhoeae, Bordetella pertussis, Campylobacter jejuni
H. influenzae: azithromycin > erythromycin > clarithromycin

Atypical/intracellular organisms (key indication):

Mycoplasma pneumoniae, Chlamydia spp., Legionella pneumophila, Ureaplasma

Mycobacteria:

Clarithromycin: Mycobacterium avium complex (MAC), M. leprae
Azithromycin: MAC prophylaxis in AIDS (once-weekly)

Other:

H. pylori (clarithromycin - component of triple therapy)
Toxoplasma, Cryptosporidium, Plasmodium spp. (azithromycin/clarithromycin)

- Lippincott Illustrated Reviews Pharmacology, pp. 998-999; Goodman & Gilman's, pp. 1202-1203

Resistance Mechanisms

Four main mechanisms (Lippincott, p. 999):

Inability to take up the antibiotic (reduced permeability in gram-negatives)
Active efflux pumps - mef gene (M phenotype); low-level resistance, common in S. pneumoniae
Ribosomal methylation - erm gene encodes a methylase that methylates adenine in 23S rRNA of the 50S subunit (MLS phenotype: cross-resistance to macrolides, lincosamides, and streptogramin B); high-level resistance
Erythromycin esterases - plasmid-encoded; gram-negative Enterobacteriaceae

Cross-resistance: strains resistant to erythromycin are usually also resistant to clarithromycin and azithromycin. - Tietz Textbook of Laboratory Medicine; Harrison's Principles of Internal Medicine 22e

Pharmacokinetics

Property	Erythromycin	Clarithromycin	Azithromycin
Acid stability	Unstable (enteric-coated or esterified formulations required)	Stable	Stable
Food effect	Reduces absorption	Increases absorption (XR form)	Reduces absorption
Bioavailability	Variable	~50-55%	~30-40%
Half-life	Short	3-7 h	40-68 h (tissue sequestration)
Active metabolite	-	14-hydroxyclarithromycin (t1/2 5-9 h)	-
Tissue distribution	Good	Good (including middle ear)	Extremely high (phagocyte accumulation); does NOT penetrate CSF or brain well
Elimination	Hepatic/biliary	Renal (20-40% unchanged); dose adjust if CrCl <30 mL/min	Biliary (only 12% urine)
IV available	Yes	No	Yes

The prolonged half-life of azithromycin (up to 68 h) arises from extensive tissue sequestration and allows once-daily (or once-weekly for MAC prophylaxis) dosing. - Goodman & Gilman's, pp. 1202-1203

Therapeutic Uses

Community-acquired pneumonia (atypical and typical): first-line agents
Whooping cough (Bordetella pertussis): most effective in the catarrhal phase - Sherris Medical Microbiology
Chlamydial infections (urogenital, respiratory): azithromycin or doxycycline preferred
H. pylori eradication: clarithromycin + amoxicillin + PPI (triple therapy)
MAC treatment and prophylaxis: clarithromycin-based regimens; azithromycin alternative
Legionnaires disease: azithromycin or fluoroquinolones
Corynebacterium diphtheriae carrier state: erythromycin or penicillin
Skin and soft tissue infections: alternative in penicillin-allergic patients
Prokinetic agent: erythromycin mimics motilin, used in diabetic gastroparesis (250-500 mg doses cause GI smooth muscle contraction) - Goodman & Gilman's, p. 1685

Adverse Effects

GI effects (most common, especially erythromycin):

Nausea, vomiting, abdominal cramps - partly due to motilin receptor agonism
Higher doses can produce spastic small bowel contractions, impairing transit

Cardiac toxicity:

QT prolongation and ventricular tachyarrhythmias (including torsades de pointes) with erythromycin, clarithromycin, and azithromycin
A large cohort study found a small but statistically significant increase in sudden cardiac death risk with azithromycin vs. no antibiotic or amoxicillin
Risk heightened by concurrent antiarrhythmics or other QTc-prolonging drugs - Goodman & Gilman's, p. 1204

Hepatotoxicity:

Cholestatic hepatitis most commonly with erythromycin estolate (after 10-20 days of use)
Characterized by nausea, vomiting, cramps -> jaundice, fever, eosinophilia, elevated transaminases
Lower risk with clarithromycin and azithromycin

Ototoxicity:

Auditory impairment and tinnitus, especially at higher doses

Allergic reactions:

Fever, eosinophilia, skin rash (uncommon; resolve after stopping drug)

Drug Interactions (CYP3A4)

This is a clinically important class effect:

Erythromycin and clarithromycin: potent CYP3A4 inhibitors - significantly increase levels of carbamazepine, cyclosporine, digoxin, ergot alkaloids, theophylline, triazolam, valproate, warfarin, statins, and calcium channel blockers
Azithromycin: much weaker CYP3A4 inhibitor - far fewer interactions, preferred when co-prescribing with CYP3A4-metabolized drugs
Erythromycin and some derivatives are metabolized by CYP3A4 to metabolites that complex the cytochrome P450 heme iron, rendering it catalytically inactive
Rifampin (CYP inducer) reduces clarithromycin concentrations
Goodman & Gilman's, pp. 1204-1205; Katzung's Basic and Clinical Pharmacology 16e

Recent Evidence

Recent systematic reviews highlight an evolving role for macrolides:

A 2024 systematic review and meta-analysis (PMID 39326270) confirmed the efficacy of long-term macrolide therapy (primarily azithromycin) in reducing exacerbations and improving lung function in non-cystic fibrosis bronchiectasis
A 2026 network meta-analysis (PMID 41534709) evaluated anti-inflammatory therapies in bronchiectasis, positioning macrolides among the most effective agents
A 2025 meta-analysis (PMID 39383346) on macrolide-resistant Mycoplasma pneumoniae in children found tetracyclines (doxycycline) superior to macrolides when resistance is present - an important clinical consideration given rising macrolide-resistant M. pneumoniae prevalence globally

This is a shared conversation. Sign in to Orris to start your own chat.